Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
It is becoming increasingly acknowledged that people with Type 2 Diabetes represent what can be termed "an enriched population": a group that has the greatest risk of morbidity and mortality from cardiovascular diseases such as myocardial infarcts and strokes. Due to the tremendous toll, both human and financial, that these cardiovascular diseases result in, major efforts are being put forth to decrease their occurrence. It is clear that success in this endeavor is optimized by achieving target levels of glucose, blood pressure, and cholesterol. Analysis of the individual drugs used to treat these comorbidities of the cardiovascular dysmetabolic syndrome has brought an understanding that frequently monotherapy is ineffective, and a clear appraisal of the benefits of available pharmaceuticals can result in a successful decision about which agents to include in regimens of combination therapy. This success translates into ultimately reducing the untimely death and disability that is unfortunately all too common among the people with these illnesses. As diabetes continues to be increasing alarmingly among all segments of the population, there is an urgency for this need. The knowledge is present; only the application is not.